Preclinical and clinical safety studies on DNA vaccines

被引:96
作者
Schalk, Johanna A. C.
Mooi, Frits R.
Berbers, Guy A. M.
van Aerts, Leon A. G. J. M.
Ovelgonne, Hans
Kimman, Tieerd G.
机构
[1] Natl Inst Publ Hlth & Environm, Ctr Biol Med & Med Technol, NL-3720 BA Bilthoven, Netherlands
[2] Natl Inst Publ Hlth & Environm, Lab Vaccine Preventable Dis, NL-3720 BA Bilthoven, Netherlands
来源
HUMAN VACCINES | 2006年 / 2卷 / 02期
关键词
DNA vaccines; safety; integration; vertical transmission; auto-immunity; immunological tolerance; immunotoxicity; toxicity; environmental safety;
D O I
10.4161/hv.2.2.2620
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
DNA vaccines are based on the transfer of genetic material, encoding an antigen, to the cells of the vaccine recipient. Despite high expectations of DNA vaccines as a result of promising preclinical data their clinical utility remains unproven. However, much data is gathered in preclinical and clinical studies about the safety of DNA vaccines. Here we review current knowledge about the safety of DNA vaccines. Safety concerns of DNA vaccines relate to genetic, immunologic, toxic, and environmental effects. In this review we provide an overview of findings related to the safety of DNA vaccines, obtained so far. We conclude that the potential risks of DNA vaccines are minimal. However, their safety issues may differ case-by-case, and they should be treated accordingly.
引用
收藏
页码:45 / 53
页数:9
相关论文
共 90 条
[31]   DNA vaccines: Immunology, application, and optimization [J].
Gurunathan, S ;
Klinman, DM ;
Seder, RA .
ANNUAL REVIEW OF IMMUNOLOGY, 2000, 18 :927-974
[32]   Lack of toxicity and persistence in the mouse associated with administration of candidate DNA- and modified vaccinia virus Ankara (MVA)-based HIV vaccines for Kenya [J].
Hanke, T ;
McMichael, AJ ;
Samuel, RV ;
Powell, LAJ ;
McLoughlin, L ;
Crome, SJ ;
Edlin, A .
VACCINE, 2002, 21 (1-2) :108-114
[33]   On the fate of plant or other foreign genes upon the uptake in food or after intramuscular injection in mice [J].
Hohlweg, U ;
Doerfler, W .
MOLECULAR GENETICS AND GENOMICS, 2001, 265 (02) :225-233
[35]  
Ichino M, 1999, J IMMUNOL, V162, P3814
[36]   Gene immunization may induce secondary antibodies reacting with DNA [J].
Isaguliants, MG ;
Iakimtchouk, K ;
Petrakova, NV ;
Yermalovich, MA ;
Zuber, AK ;
Kashuba, VI ;
Belikov, SV ;
Andersson, S ;
Kochetkov, SN ;
Klinman, DM ;
Wahren, B .
VACCINE, 2004, 22 (11-12) :1576-1585
[37]   Activity and safety of DNA plasmids encoding IL-4 and IFN gamma [J].
Ishii, KJ ;
Weiss, WR ;
Ichino, M ;
Verthelyi, D ;
Klinman, DM .
GENE THERAPY, 1999, 6 (02) :237-244
[38]   Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox [J].
Jackson, RJ ;
Ramsay, AJ ;
Christensen, CD ;
Beaton, S ;
Hall, DF ;
Ramshaw, IA .
JOURNAL OF VIROLOGY, 2001, 75 (03) :1205-1210
[39]  
Kanellos T, 1999, IMMUNOLOGY, V96, P307, DOI 10.1046/j.1365-2567.1999.00688.x
[40]   Safety evaluation of GX-12, a new HIV therapeutic vaccine: Investigation of integration into the host genome and expression in the reproductive organs [J].
Kang, KK ;
Choi, SM ;
Choi, JH ;
Lee, DS ;
Kim, CY ;
Ahn, BO ;
Kim, BM ;
Kim, WB .
INTERVIROLOGY, 2003, 46 (05) :270-276